Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Marketing
Novartis, Sarepta tipped to drive genomic therapy sales boom
GlobalData tipped the market to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta’s Elevidys and Novartis’ Zolgensma.
Nick Paul Taylor
May 15, 2025 12:18pm
Bluebird investor reluctance pays off with better buyout offer
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am
Sarepta sees delays in treatment after Elevidys death report
May 7, 2025 8:03am
As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive
Apr 11, 2025 10:32am
Novartis unveils $23B investment to beef up US manufacturing, R&D
Apr 10, 2025 3:18pm
More News
AmplifyBio shutters amid tough cell and gene therapy market
Apr 7, 2025 10:38am
FDA turmoil compounds challenges for cell and gene therapy field
Apr 2, 2025 3:16pm
Artis BioSolutions launches with acquisition of Landmark Bio
Apr 2, 2025 10:22am
CBER chief Peter Marks resigns from FDA
Mar 31, 2025 10:50am
See more stories
